Loading...
•
Jun 30, 2021
Zentalis Q2 2021 Earnings Report
Reported promising new interim data on both ZN-c3 and ZN-c5, highlighting their potentially best-in-class profiles.
Key Takeaways
Zentalis Pharmaceuticals reported financial results for the second quarter ended June 30, 2021. The company raised approximately $173 million in gross proceeds from a recent follow-on offering and had significant clinical and regulatory advances.
Reported promising new interim data on both ZN-c3 and ZN-c5.
Dosed the first patient in a potentially registrational Phase 2 trial of ZN-c3 in patients with uterine serous carcinoma (USC).
Raised approximately $173 million in gross proceeds from recent follow-on offering.
ZN-c3 demonstrated additional deepening and durable tumor responses, identifying potential accelerated approval paths in USC and a biomarker-driven setting.
Zentalis
Zentalis
Forward Guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of June 30, 2021, together with the net proceeds from its July 2021 follow-on offering, will enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2023.